Get started

Biotechstock

Possibly the most undervalued stock on the TSX!- $19M mkt cap / 11M float - $28.4M cash eq. - $17.1M Q3 revenue / $7M adjusted EBITDA - Options at $3.27 - Warrants at $3.53 - Enterprise value (as of Sep 30, 2021): $103.8M!! - Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics. - 17 Global Distribution Partners across 31 Countries. - Over 100 global patents and patent applications - 20+ products, 7 proprietary products, ~ 100 employees
MLong
by wealth_bakery
ONTX Onconova Therapeutics good results = good growthThere’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price going, at present, to position himself about a 15% below. In addition, there has been a reverse split of stocks that reduces the number of shares outstanding, so the value of each individual share should increase significantly. The advisor Marketmiracle has in fact emitted a signal LONG on the Stock to the price of 6,64 usd with a target of 622 usd that is a vertical takeoff of 9268% identifying a massive entry of capitals and of interest LONG on the Stock from some great investor. Let’s just stay grounded and figure it out on the graph. The graph tells us that surely the title has the ability to climb without virtually obstacles to the resistance indicated, we see them further signs and we will reason whether the great climb should continue or not. A greater interest in biotechs and pharmaceuticals that for some time had been put aside gives us more reason to believe that the increase in price can actually take place ( see related ideas ) This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
OLong
by MarketMiracleAdvisor
7
MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count. From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
CSE:MVMDLong
by wealth_bakery
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined Company pre-funding Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor. Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank. Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
A
by AlenCiken
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo. Statistically significant OS benefit in efti group observed in pre-defined patient groups: +7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age +9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action Collection of OS data ongoing, with final data expected to be reported mid 2021 finance.yahoo.com
NASDAQ:IMMP
by AlenCiken
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are expected to start by the end of 2021 finance.yahoo.com
NASDAQ:PRQR
by AlenCiken
$bntc Skyrocket as Morgan Stanley Takes StakeBenitec Shares Skyrocket as Morgan Stanley Takes Stake $BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company. The stake amounts to 249,174 shares, or about $1.51 million. Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration,” the company said. “The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.” www.thestreet.com
NASDAQ:BNTC
by AlenCiken
Rubraca® Significantly Improves Progression-Free SurvivalClovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus chemotherapy The safety of Rubraca observed in the ARIEL4 study was highly consistent with both the U.S. and EU product labels.
C
by AlenCiken
$IMTX positive clinical data update from Phase 1 trialsImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs ·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation ·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products ·Treatment-emergent adverse events were transient and manageable finance.yahoo.com
NASDAQ:IMTX
by AlenCiken
$ZCMD Zhongchao Renews Contract with China Association of HealthZhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline Extending the Cooperation in Pulmonary Arterial Hypertension $ZCMD yesterday announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals" ("PAH Project") in 2021. finance.yahoo.com
NASDAQ:ZCMD
by AlenCiken
$RUBY Doubles on Progress in Early-Stage Cancer-Drug TrialRubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity. RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells into Tumor Microenvironment Initial Clinical Data Provide Evidence of Broad Potential of RED PLATFORM® Across Pipeline of Cancer and Autoimmune Programs The initial data "demonstrate that RTX-240 has the potential to generate single-agent activity in patients with solid tumors, including a cold tumor such as metastatic uveal melanoma, where other treatments have failed to induce responses in patients," Christina Coughlin, an oncologist and immunologist who is chief medical officer at Rubius Therapeutics, said in a statement. “The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary efficacy data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer," Coughlin added. The ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors resulted in a 54% confirmed partial response rate in reducing the target lesions in a patient with metastatic anal cancer. The adverse effects of the treatment included fatigue, chills, nausea, decreased appetite and arthralgia, which is pain in a joint. Rubius is now planning a new Phase 1 study for the second half of 2021 to evaluate the combination of RTX-240 and another therapy. It's also planning a Phase 2 expansion cohort for first-quarter 2022, according to its statement. www.thestreet.com finance.yahoo.com
R
by AlenCiken
$INVO Expands Amended U.S. Commercialization AgreementINVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement $INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions. The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021.
I
by AlenCiken
BTIG buy recommendation with $14.00 price target- 360.5% upsideShares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday. BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept study evaluating SLS-002 in treating acute suicidal ideation and behavior in patients with major depressive disorder. Seelos also has two other clinical-stage candidates. It's evaluating SLS-005 in phase 2 studies for three neurodegenerative disorders: amyotrophic lateral sclerosis (ALS), rare genetic disease Sanfilippo syndrome, and oculopharyngeal muscular dystrophy. Seelos should report key data from its study of SLS-002 in the second quarter of this year. Seelos also plans to advance SLS-005 into a pivotal phase 2b/3 clinical study targeting ALS in the first half of the year. www.fool.com seekingalpha.com
S
by AlenCiken
$ENTX Entera Bio Ltd Announces Positive Topline EB613 Phase 2Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data ‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo. ‒ Similar to the increase in P1NP, a significant increase in Osteocalcin was also observed in the 2.5 mg group after 3 months (P <0.01). ‒ In line with a potential anabolic effect, a significant decrease in CTX was observed after 3 months of treatment (P <0.015). The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMDand a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment. ‒ Entera intends to submit the full dataset for publication and/or presentation at an upcoming medical conference.
NASDAQ:ENTX
by AlenCiken
NLS Obtains License to Full Regulatory Data Package and know-howNLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol) Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S. $NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby the Company has obtained, on an exclusive basis in the United States, all of the available data referred to and included in the original NDA for Sanorex® (mazindol) submitted to the United States Food and Drug Administration in February 1972. The Agreement encompasses all preclinical and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety reports from 1973 forward. Under the Agreement, NLS has obtained the same rights on an non-exclusive basis in all territories outside of the U.S, except for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed territories. finance.yahoo.com
NASDAQ:NLSP
by AlenCiken
Why $EYES Skyrocketed 1233% in March?$EYES Receives FDA Approval for the Argus 2s Retinal Prosthesis System $EYES today announced U.S. FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development. In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing. A decision on when or if to begin production of the newly approved hardware is pending completion of Second Sight’s planned business combination with Pixium Vision, which currently is in progress. Should the business combination be completed, the new management team will then evaluate how best to proceed with the Argus 2s Retinal Prosthesis System, as well as all other products in development. finance.yahoo.com
E
by AlenCiken
Takeda Secures Global Rights from Ovid TherapeuticsTakeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome. Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations. In addition, Ovid will receive tiered royalties beginning in the low double-digits and up to 20 percent on sales of soticlestat, if approved and commercialized. Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021. finance.yahoo.com
NASDAQ:OVID
by AlenCiken